BROCA Cancer Risk Panel
General Information
Lab Name
BROCA Cancer Risk Panel
Lab Code
BROCA
Epic Name
BROCA Cancer Risk Panel
Description
BROCA Cancer Risk panel is useful for the germline (only) evaluation of patients with a suspected hereditary cancer predisposition. Depending on the causative gene involved, these cancers may co-occur with other cancer types (such as colorectal, endometrial, pancreatic, endocrine, or melanoma).
BROCA uses next-generation sequencing to detect most variants in
ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, BMPR1A, BRCA1*, BRCA2*, BRIP1, CDH1, CDK4, CDK12, CDKN2A, CHEK2, CTNNA1, DICER1, EPCAM, FANCM, FH, FLCN, GEN1, GREM1, HOXB13, MEN1, MET, MITF, MLH1*, MLH3, MSH2*, MSH3, MSH6*, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PHOX2B, PIK3CA, PMS2*, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RECQL, RET, RNF43, RPS20, SDHA, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TP53, TSC1, TSC2, and VHL. The assay completely sequences all exons of these genes AND detects large deletions and duplications.
- The test uses next-generation sequencing to detect pathogenic variants in the genes listed in the table below. The assay completely sequences exons and flanking intronic sequences of all the genes on the panel, and promotor regions of select genes. The assay detects single nucleotide variants, small insertions, and deletions (indels), large deletions, duplications, and constitutional mosaicism. For genes indicated with *above, full intronic regions are sequenced and analyzed.
- Custom BROCA can be ordered by specifying genes for which testing is requested on the Genetics Requisition; pricing is the same as the full BROCA Cancer Risk Panel.
- For an overview of available germline and paired tumor-germline testing for hereditary cancer syndromes, please see: Hereditary Cancer Test Menu: Germline and Paired Tumor-Germline guideline.
- Single Gene Analysis [SGN] (next generation sequencing) can be ordered for any gene on the BROCA panel.
- Known Mutation Testing [KMU] testing can be requested for relatives of probands with pathogenic/likely pathogenic variants previously detected via testing at the UW Genetics Laboratory.
BROCA Gene List
Gene |
Function/Pathway |
Heterozygote Cancer risk* |
Associated syndrome |
References (PMID) |
ALK |
MYC signaling |
Neuroblastoma |
||
APC |
WNT signaling |
Colon |
Familial adenomatous polyposis |
|
ATM |
Double stranded break repair |
Breast, Pancreatic |
Ataxia telangiectasia (recessive) |
|
ATR |
Double stranded break repair |
Oropharyngeal |
Seckel (recessive) |
|
AXIN2 |
Colon |
Oligodontia-colorectal cancer syndrome |
||
BAP1 |
BRCA1-associated protein complex |
Uveal Melanoma, Mesothelioma |
BAP1 Tumor predisposition syndrome | |
BARD1 |
BRCA1-associated protein complex |
Breast, Ovarian |
Hereditary breast cancer | |
BMPR1A |
TGF-beta signaling |
Colon |
Juvenile polyposis |
|
BRCA1 |
BRCA1-associated protein complex |
Breast, Ovarian |
Hereditary breast and ovarian cancer |
|
BRCA2 |
Fanconi/BRCA |
Breast, Ovarian |
Hereditary breast and ovarian cancer, Fanconi anaemia FA-D1 (recessive) |
|
BRIP1 |
Fanconi/BRCA |
Breast, Ovarian |
Fanconi anaemia FA-J (recessive) |
|
CDH1 |
Cell adhesion |
Breast, Gastric |
Hereditary diffuse gastric cancer |
|
CDK4 |
Cell cycle |
Melanoma |
Familial melanoma | |
CDK12 |
MAP kinase regulation | Breast, Ovarian | Typically somatic only; Hereditary breast and ovarian cancer | |
CDKN2A |
Cell cycle |
Pancreatic, Melanoma |
Familial melanoma and pancreatic cancer | |
CHEK2 |
Double stranded break repair |
Breast |
Hereditary breast cancer | |
CTNNA1 |
Beta-catenin, e-cadherin complex |
Gastric |
Hereditary diffuse gastric cancer |
|
DICER1 |
Tumor suppressor |
Wilms tumor, pleuropulmonary blastoma |
DICER1 syndrome |
|
FANCM |
Fanconi/BRCA |
Breast |
Fanconi anemia (recessive) |
|
FH |
Tumor suppressor |
Renal |
Hereditary leiomyomatosis and renal cell cancer |
|
FLCN |
Tumor suppressor |
Renal |
Birt-Hogg-Dube syndrome |
|
GEN1 |
Double stranded break repair |
Breast |
Breast | |
GREM1 |
BMP antagonist |
Colon |
Hereditary mixed polyposis syndrome |
|
HOXB13 |
transcription factor |
Prostate |
Familial prostate cancer | |
MEN1 |
Gene expression regulation |
Endocrine |
Multiple endocrine neoplasia type 1 |
|
MET |
Tyrosine Kinase receptor |
Kidney, Squamous cell carcinomas |
Hereditary papillary renal cell carcinoma | |
MITF |
Melanocyte inducing transcription factor |
Kidney, Melanoma |
MITF-related melanoma and renal cell carcinoma predisposition | |
MLH1 |
Mismatch DNA repair |
Colon, Ovarian, Endometrial |
Lynch syndrome |
|
NEW MLH3 |
Mismatch DNA repair |
Polyposis (recessive) |
Unknown (recessive) | |
MSH2 / EPCAM |
Mismatch DNA repair |
Colon, Ovarian, Endometrial |
Lynch syndrome |
|
MSH3 |
Mismatch DNA repair |
Polyposis (recessive) |
Familial adenomatous polyposis 4 (recessive) | |
MSH6 |
Mismatch DNA repair |
Colon, Endometrial |
Lynch syndrome |
|
MUTYH |
DNA repair |
Colon (homozygotes) |
MUTYH-associated polyposis |
|
NBN |
Double stranded break repair |
Breast |
Nijmegen breakage syndrome (recessive) |
|
NF1 |
MAPK signaling |
Optic Glioma, Peripheral Nerve Sheath, Breast |
Neurofibromatosis |
|
NF2 |
Cellular regulation |
Acoustic neuromas, Vestibular Schwannomas |
Neurofibromatosis 2 |
|
NTHL1 |
Base excision repair |
Colon |
Polyposis (recessive) |
|
PALB2 |
Fanconi/BRCA |
Breast, Pancreatic |
Fanconi anaemia FA-N (recessive) |
|
PHOX2B |
Tumor suppressor |
Neuroblastoma |
Hereditary neuroblastoma | |
PIK3CA |
AKT signaling |
Breast, Thyroid |
Cowden-like |
|
PMS2 |
Mismatch DNA repair |
Colon, Endometrial |
Lynch syndrome |
|
POLD1 |
DNA Polymerase |
Colon, Endometrial |
Familial polyposis, colorectal cancer |
|
POLE |
DNA Polymerase |
Colon |
Familial polyposis, colorectal cancer |
|
POT1 |
Telomere maintenance |
Brain, Melanoma |
Familial melanoma and brain cancer |
|
PRKAR1A |
cAMP signaling |
Endocrine |
Carney complex (recessive) |
|
PTCH1 |
Hedgehog |
Basal cell carcinoma, PNET |
Nevoid basal cell-carcinoma syndrome |
|
PTEN |
PI3K/MAPK Signaling |
Breast |
Cowden syndrome |
|
RAD51B |
Double stranded break repair |
Unknown |
Hereditary breast and ovarian cancer | |
RAD51C |
Fanconi/BRCA |
Ovarian, Breast |
Fanconi anaemia FA-O (recessive) |
|
RAD51D |
Fanconi/BRCA |
Ovarian, Breast |
Fanconi anemia (recessive) | |
RB1 |
Tumor suppressor |
Retinoblastoma, Sarcoma, Melanoma |
Hereditary retinoblastoma |
|
RECQL |
DNA repair |
Breast |
Hereditary retinoblastoma | |
RET |
Receptor Tyrosine Kinase |
Endocrine |
Multiple endocrine neoplasia type 2 |
|
NEW RNF43 |
WNT signaling |
Serrated polyposis |
Sessile Serrated Polyposis | |
RPS20 |
Ribosomal protein |
Colon |
unknown | |
SDHA | Succinate dehydrogenase complex |
Pheochromocytoma, Paraganglioma |
Hereditary paraganglioma-pheochromoctyoma | 20484225, 21752896 |
SDHB |
Succinate dehydrogenase complex |
Pheochromocytoma, Paraganglioma |
Hereditary paraganglioma-pheochromoctyoma |
|
SDHC |
Succinate dehydrogenase complex |
Pheochromocytoma, Paraganglioma |
Hereditary paraganglioma-pheochromoctyoma |
|
SDHD |
Succinate dehydrogenase complex |
Pheochromocytoma, Paraganglioma |
Hereditary paraganglioma-pheochromoctyoma |
|
SMAD4 |
TGF-beta signaling |
Colon |
Juvenile polyposis |
|
SMARCA4 |
SWI/SNF complex |
Ovarian |
Hereditary small cell carcinoma of the ovary, hypercalcemic | |
STK11 |
Tumor suppresso |
Breast, Pancreas, Other cancers |
Peutz-Jeghers syndrome | 20301443 |
TP53 |
Cell growth |
Breast, Ovarian |
Li-Fraumeni syndrome |
|
TSC1 |
Cell growth |
Hamartomas |
Tuberous sclerosis complex |
|
TSC2 |
Cell growth |
Hamartomas |
Tuberous sclerosis complex |
|
VHL |
p53 regulation |
Kidney, Neuroendocrine |
von Hippel-Lindau syndrome |
*Only the most commonly associated cancer types are listed. A more detailed description of cancer risk for some BROCA genes can be found at GeneReviews.
For previous versions of BROCA Cancer Risk Panel, see Previous Versions, BROCA.
References
- Walsh T, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A 2010, 107:12629-33. 20616022
- Walsh T, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 2011, 108:18032-7. 22006311
- Nord AS, Lee M, King MC, and Walsh T. Accurate and exact CNV identification from targeted high-throughput sequence data. BMC Genomics 2011, 12:184. 21486468
- Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010, 11:31-46. 19997069
- Shirts BH, et al. Improving performance of multigene panels for genomic analysis of cancer predisposition. Genet Med 2016, 18:974-81. 26845104
For providers interested in more information on interpreting genetic test results for your patient, please see the Guide to Interpreting Genomic Reports: A Genomics Toolkit
Synonyms
ALK, and VHL., APC, ATM, ATR, AXIN2, BAP1, BARD1, BMPR1A, BRCA1*, BRCA2*, Breast Cancer, BRIP1, CDH1, CDK12, CDK4, CDKN2A, CHEK2, CTNNA1, DICER1, EPCAM, FANCM, FH, FLCN, GEN1, GREM1, Hereditary Cancer panel, HOXB13, MEN1, MET, MITF, MLH1*, MLH3, MSH2*, MSH3, MSH6*, multi-gene panel, MUTYH, NBN, Next-generation sequencing, NF1, NF2, NTHL1, Ovarian Cancer, PALB2, Paraganglioma, Pheochromocytoma, PHOX2B, PIK3CA, PMS2*, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RECQL, RET, RNF43, RPS20, SDHA, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, Succinate dehydrogenase, TP53, TSC1, TSC2
Components
Code | Name |
---|---|
BROCGS | BROCA Genes Sequenced |
BROCRE | BROCA Result |
BROCIN | BROCA Interpretation |
BROCCH | BROCA Clinical History |
BROCMT | BROCA Method |
BROCDI | BROCA Director |
Interpretation
Method
Next-generation sequencing.
This assay sequences all exons and flanking intronic sequences of ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, BMPR1A, BRCA1*, BRCA2*, BRIP1, CDH1, CDK4, CDK12, CDKN2A, CHEK2, CTNNA1, DICER1, EPCAM, FANCM, FH, FLCN, GEN1, GREM1, HOXB13, MEN1, MET, MITF, MLH1*, MLH3, MSH2*, MSH3, MSH6*, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PHOX2B, PIK3CA, PMS2*, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RECQL, RET, RNF43, RPS20, SDHA, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TP53, TSC1, TSC2, and VHL. Sequences are aligned to the human genome reference (hg19). Test performed by targeted capture for listed genes followed by next-generation sequencing with Illumina technology. This test was developed and its performance characteristics determined by the University of Washington Department of Laboratory Medicine. It has not been cleared or approved by the US Food and Drug Administration. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.
Reference Range
See individual components
Ref. Range Notes
No mutations detected
Guidelines
Ordering & Collection
Specimen Type
Collection
BLOOD:
Preferred: 10 mL whole blood in LAVENDER TOP EDTA tube.
Also acceptable: YELLOW TOP ACD tube, purified DNA from peripheral blood or cultured cells.
SALIVA:
Contact laboratory for validated collection kit.
Forms & Requisitions
Genetics Preauthorization Form (preauthorization is only done for providers who are external to the UW system).
- Fill out a Genetics Requisition form.
- Under "Check Test Requested," check: "BROCA - Cancer Risk Panel".
- For single gene next-generation sequencing or known muatation testing, see Single Gene Analysis [SGN] or Known Mutation Testing [KMU].
- To order a subset of genes on the BROCA panel, check: "BROCA - Cancer Risk Panel" and note the genes for which testing is being ordered. Custom BROCA pricing is the same as full BROCA panel.
- To order BROCA Paired Tumor, check "BROCA Paired Tumor Panel" and “Normal control”. All BROCA Paired Tumor testing on tumor tissue requires a copy of pathology report to be sent along with the Genetics Requistion form.
- To order BROCA on fresh tissue, tumor tissue, cultured fibroblasts, amniocytes, please order BROCA Paired Tumor Panel; a second control sample is not required for germline assessment of normal tissue or cultured cells.
Handling Instructions
Ship specimen at room temperature for overnight delivery.
Blood specimens can be held for up to 7 days before shipping if refrigerated.
Ship specimens to:
UW MEDICAL CENTER
LABORATORY MEDICINE - GENETICS LAB
1959 NE PACIFIC ST, ROOM NW220
SEATTLE, WA 98195-7110
Quantity
requested: entire sample
minimum: 5 mL whole blood (adult); 2 mL whole blood (pediatric)
Processing
Blood: Refrigerate whole blood
Unacceptable Conditions: Frozen or clotted specimens
Stability (collection to initiation of testing): Ambient: 5 days; Refrigerated: 7 days; Frozen: Unacceptable
Purified DNA: Refrigerate DNA specimens. Frozen is acceptable.
Performance
LIS Dept Code
Genetics (GEN)
Performing Location(s)
UW-MT |
Genetics
Attention: Genetics Lab Tel: 206-598–6429 M–F (7:30 AM–4:00 PM) Tel (EXOME only): 206-543-0459 |
Faculty |
---|
Frequency
Typical Turnaround: 4 weeks *Turn around times may vary based on factors such as tissue acquisition and insurance preauthorization.
Available STAT?
No
Billing & Coding
CPT codes
Billing Comments
For additional test/billing information, see following page, CPT codes for Hereditary Cancer Panels (germline and paired).
For pricing information, contact Client Support Services 206-520-4600 or 800-713-5198.
Billing and Insurance Pre-Authorization
We offer insurance pre-authorization services (preauthorization is only done for providers who are external to the UW system).
Email: gpab@uw.edu or call 1-855-320-4869 for more information.
LOINC
Interfaced Order Code
UOW2684